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Abstract The expansion of the biologics pipe-
line depends on the identification of candidate
proteins for clinical trials. Speed is one of the
critical issues, and the rapid production of high
quality, research-grade material for preclinical
studies by transient gene expression (TGE) is
addressing this factor in an impressive way:
following DNA transfection, the production
phase for TGE is usually 2–10 days. Recombinant
proteins (r-proteins) produced by TGE can
therefore enter the drug development and screen-
ing process in a very short time––weeks. With
‘‘classical’’ approaches to protein expression from
mammalian cells, it takes months to establish a
productive host cell line. This article summarizes
efforts in industry and academia to use TGE to
produce tens to hundreds of milligrams of r-
proteins for either fundamental research or pre-
clinical studies.
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Introduction
The production of recombinant proteins (r-pro-
teins) has been an important technology over the
last twenty years with the main focus being on
biopharmaceutical products with medical appli-
cations. Most r-proteins in this category are
complex molecules that need to be post-transla-
tionally modified for full bioactivity. As such
modifications are only accurately performed by
mammalian cells, they have become the major
host for complex r-protein expression (Wurm
2004). Pharmaceutical companies routinely estab-
lish recombinant cell lines that constitutively
produce r-proteins for extended cultivation times.
This stable gene expression is achieved through
the insertion of the recombinant gene(s) into the
host genome. However, identification and char-
acterization of recombinant cell lines is a costly
and time-consuming process. Faster approaches
to r-protein production are sometimes preferred
when one must rapidly evaluate many candidate
proteins or when several variants of a single
protein need to be studied for their potential as
biologics. Transient gene expression (TGE) is
well-suited to fill this need. In contrast to stable
gene expression, TGE involves short-term r-
protein production typically for up to 10 days
post-transfection in the absence of genetic selec-
tion of the plasmid DNA. Secreted, membrane,
and intracellular proteins have been successfully
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expressed by TGE (Meissner et al. 2001; Geisse
and Henke 2005; Shi et al. 2005), and high-
throughput approaches for TGE in human
embryonic kidney (HEK 293) cells have recently
been described for the production of G-protein
coupled receptors (Davies et al. 2005). This
review emphasizes the main advantages and
drawbacks of large-scale TGE performed with
suspension cultures of mammalian cells (the term
‘‘large scale’’ is implied for work with cultures
greater than 1 l in working volume) and describes
challenges for further improvement of the
technology.
Expression vectors
Different expression vectors, both non-viral and
viral, have been designed to transfer foreign
genes into mammalian cells. The choice of the
vector depends on the application, the host cell,
the time limitation, the level of desired product,
and safety. Only a brief overview of this subject is
provided here. Additional information may be
found in recent reviews (Makrides 1999; Van
Craenenbroeck et al. 2000).
Non-viral expression vectors
Essential elements of typical TGE vectors include
(1) a constitutive or inducible promoter; (2) a
transcription terminator; and (3) a prokaryotic
cassette with a replication origin and a selection
marker for vector production in bacteria. Most of
the commonly used strong constitutive promoters
are from viral genomes including the human
cytomegalovirus (HCMV) immediate early pro-
moter, the simian virus 40 (SV40) early promoter,
and Rous sarcoma virus long-terminal repeat
promoter. Cellular promoters such as that of the
human elongation factor-1-alpha (EF-1a) gene
have been shown to be similar in strength to the
HCMV promoter (Gill et al. 2001). Although
most cDNAs can be expressed at high levels from
a strong constitutive promoter, insertion of an
intron between the promoter and the 5¢-end of
the cDNA has been shown to increase the
r-protein expression level (Buchman and Berg
1988). Mammalian cells expressing the Epstein-
Barr virus (EBV) nuclear antigen 1 (EBNA1) or
the SV40 large-T antigen, support the episomal
amplification of vectors carrying the EBV or the
SV40 origin of replication, respectively. This
strategy improves r-protein production levels by
increasing the plasmid copy number in the trans-
fected cell population (Van Craenenbroeck et al.
2000; Young et al. 1988).
TGE requires a significant amount of plasmid
DNA. Typical protocols use about 1–1.25 lg
plasmid DNA per ml culture. DNA is thus a
major cost-factor for large-scale TGE. Two of the
most important aspects of the plasmid purification
are the recovery of a high percentage of super-
coiled DNA and the elimination of contaminants
such as bacterial RNA and endotoxin (Stadler
et al. 2004). Although it has been reported that
these contaminants do not significantly affect the
efficiency of transfection with the calcium phos-
phate (CaPi) method (Wright et al. 2003), the
removal of lipopolysaccharide (LPS) is critical in
downstream processing of the r-protein (Wakelin
et al. 2006).
Viral expression vectors
Semliki Forest virus (SFV) is the most widely
used viral expression vector for TGE. Large-scale
production of a recombinant G-protein coupled
receptor has been performed with SFV-infected
mammalian cells cultured in suspension in bior-
eactors or spinner flasks (Blasey et al. 2000;
Hassaine et al. 2006). Baculovirus vectors have
also been used to produce r-proteins in both
insect and mammalian cells (Boyce and Bucher
1996; Hofmann et al. 1995; Kost et al. 2000). The
disadvantage of using insect cells is that they are
unable to produce fully active recombinant mam-
malian glycoproteins due to the absence of
sialylation. Thus, efforts have been made to
engineer baculovirus expression systems that
allow production of humanized recombinant gly-
coproteins in insect cells (Jarvis 2003; Seo et al.
2001). For the expression of r-proteins in mam-
malian cells, baculovirus vectors have numerous
advantages including: (1) the absence of viral
replication, (2) the lack of cytotoxicity, (3) the
technical simplicity of vector production, and (4)
the large DNA insert capacity (up to 38 kb)
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allowing the delivery of multiple genes from a
single vector (Kost et al. 2000). Finally, vaccinia
virus vectors have been used to produce r-
proteins such as nerve growth factor (Edwards
et al. 1988), Factor VIII (Pavirani et al. 1987),
and human pro-thrombin (Falkner et al. 1992).
The infectious nature of the virus is a major
concern, and it requires containment in a Bio-
safety Level 2 laboratory. To reduce safety risks,
less infectious strains such as the modified vac-
cinia virus Ankara (MVA) have been used
(Sutter and Moss 1992).
Non-viral gene delivery vehicles
A multitude of physical and chemical methods
have been developed for the transfer of DNA
into cultivated mammalian cells, but only a few of
these are applicable to large-scale TGE. In
general, the chemical agents used for transfection
can be classified into inorganic compounds, cat-
ionic polymers, and cationic lipids. Among the
methods employing inorganic compounds, CaPi-
DNA coprecipitation is still the most widely used
(Jordan et al. 1996). The most efficient cationic
polymers are polyethylenimines (PEIs), most
notably either branched or linear 25 kDa PEI
(Boussif et al. 1995; Thomas and Klibanov 2003).
Even though cationic lipids are very effective
transfection agents, they have not been frequently
used for large-scale TGE due to the compara-
tively high cost. All of these chemical agents face
the same barriers regarding the delivery of
functional DNA into the nucleus of cells
(Lechardeur et al. 2005). Physical gene transfer
methods such as microinjection, electroporation,
and ballistics bypass these cellular barriers and
deliver naked plasmid DNA directly to the
nucleus. However, these methods have not been
successfully adapted to large-scale TGE.
CaPi remains one of the most efficient DNA
delivery agents, as it allows transfer of plasmid
DNA to approximately 80–90% HEK 293 cells
under some conditions (Meissner et al. 2001).
Although it is inexpensive and does not interfere
with protein recovery, there are several draw-
backs to its use including the time-sensitive
formation of the coprecipitate, making transfec-
tion of large volumes technically challenging. The
requirement for serum in the transfection med-
ium to limit the ‘‘growth’’ or aggregation of the
coprecipitate into large inefficient complexes is
another critical constraint. Furthermore, CaPi is
not an efficient delivery method for chinese
hamster ovary (CHO) cells without an osmotic
shock (Batard et al. 2001). In a variation of the
traditional CaPi method, Lindell et al. (2004)
demonstrated that addition of DNA and CaCl2
directly to a suspension culture of HEK 293 cells
(‘‘Calfection’’) resulted in the production of
about 3 mg/l antibody in a 30 l culture.
Currently, the most widely used DNA delivery
agent for large-scale TGE appears to be PEI.
Transfections with linear 25 kDa PEI have been
the most productive to date with reported IgG
yields up to 80 mg/l in HEK 293 cells (Wuhlfard
and Wurm, unpublished results) and 22 mg/l in
CHO cells (Muller 2005) (see Table 1). PEI is
moderately cytotoxic and non-biodegradable.
Importantly, the effects of residual PEI on the
downstream processing of r-proteins and on r-
protein quality have not been systematically
addressed.
Large-scale TGE
Cell lines
Several cell lines have been used for transient
expression of r-proteins, but only a few of them
present the advantages of (1) high transfectability
with common methods (2) ease of adaptation to
suspension cultivation in serum-free conditions,
and (3) cost-effective scalability. HEK 293 is the
most commonly used cell line for large-scale
transient transfection. It was created nearly
30 years ago by transformation of primary human
embryonic kidney cells with sheared fragments of
adenoviral DNA (Ad5) (Graham et al. 1977), and
they constitutively express the adenovirus E1A
and E1B genes. In order to support large-scale
adenovirus production in bioreactor cultures, this
cell line was adapted to suspension growth, and
the resulting cell line was named 293N3S
Biotechnol Lett (2007) 29:677–684 679
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(Graham 1987). Yet another cell line (293S) was
generated through gradual adaptation to serum-
free medium (Garnier et al. 1994). A subclone of
this cell line (293SF-3F6) has been further
selected for its capacity to grow at high density
(8 · 106 cells/ml) in serum-free suspension and is
frequently used for the production of adenoviral
vectors (Coˆte´ et al. 1998). In the attempt to
specifically improve TGE through promoting
episomal replication of the exogenous plasmid
DNA, two other HEK 293 derivatives have been
generated: HEK 293-T and HEK 293-EBNA that
constitutively express from stably transfected
gene the SV40 large T antigen and the EBV
EBNA1 protein, respectively (see section on non-
viral expression vectors). Another cell line
(HKB11) was derived from HEK 293 cells
through the fusion with a human B cell lymphoma
(Cho et al. 2002). This cell line was successfully
used in a 10 l Wave bioreactor system for TGE
(see below). Recently a few groups described
successful TGE in CHO cells previously adapted
to serum-free suspension growth (Derouazi et al.
2004; Rosser et al. 2005). The two strains of CHO
most commonly used for TGE are K1 and the
dihydrofolate reductase mutant DG44 (Urlaub
and Chasin 1980). These cells have been widely
used for decades in industrial laboratories. They
have a very high productivity potential and there
is a well-developed understanding of their behav-
iour in bioprocesses. In particular, when TGE is
used as screening tool for drug development, it is
Table 1 Transient expression of recombinant proteins at scale of more than 1 l final volume
Product Cells Transfection
agent
Serum Scale
(litre)
Culture
system
Maximum titer
(mg/L)
Maximum
yield (mg)
Reference
TNF-
Rp55
HEK293E PEI no 2 Erlenmeyer 0.55 n.d. Schla¨ger and
Christensen (1999)
huIgG HEK293E CaPi yes 110 10 l STR 7.7 500 Girard et al. (2002)
SEAP
(a)
HEK293E PEI yes 3.5 Helical
ribbon
20 60 Durocher et al.
(2002)
Tie-2
ED
293-SFE PEI no 14 STR n.d. 33 Pham et al. (2003)
NP-1 293-SFE PEI no 10 STR n.d. 35 Pham et al. (2003)
various HKB11 DMRIE-C no 10 WaveTM 40 (b) 400 Cho et al. (2003)
hu-IgG HEK293E Calfection yes 30 110 l STR 2.5 75 Lindell et al. (2004)
hu-IgG CHO (c) PEI no 13 20 l STR 6 n.d. Derouazi et al. (2004)
SEAP HEK293E PEI yes 1 1 l STR 25 n.d. Pham et al. (2005)
SEAP HEK
293F
PEI no 1 1 l STR 10 n.d. Pham et al. (2005)
>30 HEK293E PEI no 10 WaveTM 12 n.d. Geisse and Henke
(2005)
various HEK293E PEI no 2 Shake
bottle
27 145 Baldi et al. (2005)
hu-IgG CHO (c) PEI no 80 110 l STR 22 n.d. Muller (2005)
various
IgGs
CHO-K1s LF (d) no 1 Spinner 20 n.d. Rosser et al. (2005)
hu-IgG HEK293E PEI no 4 BiotainerTM 4.25 17 L. Baldi (e)
B2-
CD1d
HEK293E PEI no 2 Shake
bottle
n.a. 24 L. Baldi (e)
hu-IgG CHO (c) PEI no 10 BiotainerTM 17.5 n.a. M. Stettler (e)
hu-IgG CHO (c) PEI no 10 WaveTM 9 n.a. M. Stettler (e)
hu-IgG HEK293E PEI no 10 Shake
bottle
80 n.a. S. Wuhlfard (e)
(a) and 13 other proteins; (b) only 8 over 50 proteins express at titers >10 mg/l; (c) CHO DG44 cells; (d) LF, Lipofectamine;
(e) unpublished results
Abbreviations: n.d., not described; n.a., not available; DMRIE-C, 1,2-dimyristyloxypropyl-3-dimethyl-hydroxy ethyl
ammonium bromide/cholesterol; STR, stirred-tank bioreactor; HEK293E, HEK 293 EBNA; 293-SFE, HEK 293 serum-free
EBNA cells; HEK 293F, HEK 293 Freestyle (commercially available from Invitrogen).
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highly desirable to rapidly obtain CHO-derived
material for preclinical tests, as this will be the
host cell for stable cell line development.
Although there is no evidence that HEK 293-
derived r-proteins differ in any way from CHO-
derived material, the pharmaceutical industry
prefers to use CHO cell lines for production
because of their established track record. A few
successful reports of TGE in CHO at large scale
(larger than 1 l) are summarized in Table 1.
Production media
Due to intensive research into media formula-
tions for the manufacture of r-proteins, serum-
free cultures are now the standard for growth of
mammalian cells in suspension (Barnes and Sato
1980). The need to minimize animal-derived
components in production processes, both for
biosafety reasons and to facilitate downstream
processing, has created an interest in using
protein hydrolysates (peptones) as a protein
supplement to replace serum. Hence a number
of chemically defined media have been developed
which do not contain animal-derived material.
These media generally support high cell densities
and facilitate the expression and purification of r-
proteins. Most often these media have been
developed specifically for serum-free cultivation
of HEK 293 or CHO cells. Initial attempts to
perform transient transfection in these serum-free
media failed, mainly because of the presence of
polymers that hinder transfection complex stabil-
ity and uptake. Transfection in these media has
then been made possible through accurate opti-
misation of the gene delivery protocols (Derouazi
et al. 2004; Muller 2005). Supplementation of
standard protein-free media with peptones
yielded a significant increase in TGE productivity
in HEK 293-EBNA cells (Pham et al. 2003; Pham
et al. 2005).
Large-scale processes
There are only a few published reports on TGE at
scales larger than 1 l, and even less for 10 l and
more. Most of these publications have origi-
nated from academic laboratories. Large-scale
processes employ mostly standard stirred-tank
bioreactors (STR), but a recently developed
bioreactor (the WaveTM), with disposable plastic
bags, has proven to be particularly well-suited for
TGE (Geisse and Henke 2005). Disposable bior-
eactors are raising interest mainly due to their low
initial investment cost and their ease of operation,
maintenance, and validation. In addition, TGE in
non-instrumented round- or square-shaped bot-
tles of nominal volumes of 1–20 l is being
explored. In head-to-head comparisons these
containers have outperformed instrumented
bioreactors, making them an attractive, inexpen-
sive alternative for large-scale TGE (Wuhlfard,
Hildinger, Stettler and Wurm, manuscript in
preparation).
Expression level
Table 1 summarizes the publications reporting
TGE at scales of 1 l or more, together with a few
unpublished results from our laboratory. How-
ever, several leading biopharmaceutical compa-
nies are routinely employing TGE at scales up to
100 l for their drug discovery programs.
Volumetric productivity with TGE depends to
a great extent on the intrinsic structural features
of the r-protein, thus it is difficult to compare the
efficacy of various TGE protocols (Bentley et al.
1998). In general, with efficient non-viral gene
delivery agents like PEI, titers range from 1 to
80 mg/l with either CHO or HEK 293 cells
(Table 1). IgG yields in the range of 2–80 mg/l
have been achieved in instrumented bioreactors
ranging in size from 3 to 150 l using either batch
or fed-batch approaches (Meissner et al. 2001;
Girard et al. 2002).
Conclusions and future perspectives
The technology to generate research-quality
r-proteins by TGE has been under development
for more than 10 years in both academic and
industrial laboratories. During this period, the
major improvements in TGE have come via the
formulation of serum-free media that support
high-density growth of cells in suspension and
efficient serum-free transfection methods. De-
spite these advances, the specific productivity of
Biotechnol Lett (2007) 29:677–684 681
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TGE remains typically far below 10 pg/cell  day,
whereas that of some recombinant cell lines has
been reported to be over 50 pg/cell  day (Wurm
2004). It is therefore likely that the upper limit for
the specific productivity by TGE has not yet been
achieved. One of the major challenges for the
future is to close the gap between transient and
stable r-protein productivity. Another gap exists
with respect to cell number in batch processes
between transient and stable expression. Whereas
most transient protocols result in cell densities
below 3 · 106 cells/ml, optimized high-yield sta-
ble processes achieve 10–15 · 106 cells/ml over
10–14 days (Wurm 2004). While the exact nature
of the improvements are not known in detail for
proprietary reasons, it is likely that they involve
(i) the development of both serum-free and
protein-free media to support high-density culti-
vation of cells in suspension, (ii) improved feed-
ing strategies (for fed-batch cultures), and (iii) the
genetic modification of the host cells. This results
in volumetric yields of up to 5 g/l in the best cases.
Targets for cell engineering may include meta-
bolic and apoptotic pathways (Fussenegger and
Bailey 1998). For example, strategies involving
the over-expression of exogenous anti-apoptotic
genes have led to higher cell viability and
improved r-protein yield (Mastrangelo et al.
2000; Tey et al. 2000; Kim and Lee 2002). Similar
strategies are also likely to benefit TGE. As an
example, it has been shown that improved tran-
sient r-protein production results from the inhi-
bition of the cell cycle (Tait et al. 2004; Galbraith
et al. 2006). To establish more efficient host cells
for TGE through genetic manipulation, the over-
expression of exogenous genes as mentioned
above and the downregulation of host genes
through siRNA technology (Hacker et al. 2004)
should be attempted.
A very promising route and probably the best
one for providing high volumetric yields is the
increase in biomass before, during and/or after
transfection. Other improvements to TGE are
likely to come from the transfection process
itself. All of the major chemical transfection
agents used for TGE including CaPi, PEI, and
liposomes have major drawbacks as described
above. In addition, they only deliver a small
percentage of the transfected DNA (<10%) to
cells (Batard et al. 2001; Lechardeur et al. 2005).
More efficient DNA transfer would allow the
amount of plasmid DNA, a major cost factor in
addition to a major source of variability for
TGE, to be reduced. Besides increased transfec-
tion efficiency, the ideal transfection reagent will
be non-cytotoxic and will not interfere with r-
protein purification or quality. The development
of novel transfection agents such as dendrimers
(Lee et al. 2005), chemically-modified PEI (Tho-
mas et al. 2005), and chitosan (Dang and Leong
2006) continues and may lead to more efficient
delivery methods. Finally, it may be possible to
adapt physical DNA delivery methods such as
electroporation to large-scale TGE (Li et al.
2002).
Another major challenge remains the estab-
lishment of TGE as a bioprocess for the manu-
facture of r-proteins. Currently, there are no
FDA-approved r-proteins generated by TGE,
probably because it appears to be a ‘‘revolution-
ary’’ approach. In our mind, there is no reason to
prevent eventual approval of a TGE-based man-
ufacturing process. For certain low-dose products
such as erythropoietin (EPO) or granulocyte
colony-stimulating factor (G-CSF), current TGE
yields are quite sufficient to establish economi-
cally feasible processes. R-proteins used for
individualized medicine could also be manufac-
tured by TGE. This is of course not the case when
considering high-dose antibody products. For
these it will be necessary to increase the specific
productivity, the volumetric productivity and, last
but not least, the maximum operating volume for
TGE. The largest volume reported for TGE is
100 l (Girard et al. 2002), and volumes from
1–100 l are probably sufficient for the production
of milligram to gram quantities of r-proteins for
research or for pre-clinical studies. Larger TGE
processes are undoubtedly possible, but this
parameter has not been adequately explored.
Besides the issue of the feasibility of scaling-up
the production process, there is also concern that
the product heterogeneity within a batch and
from batch to batch may restrict the manufactur-
ing potential of TGE. However, not enough
detailed studies on product heterogeneity in
TGE production runs have been published to
make a conclusive statement on this point.
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Summary
The future challenges for the biotechnology
industry require a wide-angle, integrative view
spanning the cell’s metabolism (from genomics to
proteomics and metabolomics), innovative bio-
process engineering strategies for high-density,
large-scale cell cultivation, efficient gene delivery
methods, and more efficient and economical
downstream recovery and analytical methods.
Through such an integrated approach involving
both biology and engineering, we believe that in
the upcoming years specific productivity of tran-
siently transfected mammalian cells will increase
to 20–50 pg/cell  day. Combined with increased
process robustness, reproducibility, scalability
and speed, a substantial improvement in protein
yield will make TGE an option for therapeutic
protein manufacturing and open a whole new
chapter in industrial biotechnology.
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